Advertisement

Addressing Barriers for Patients with Celiac Disease When Assessing for Gluten in Medications

      Celiac disease is an autoimmune and inflammatory disorder that causes a reaction to gluten, a protein found in wheat, barley, and rye.
      • Mangione R.A.
      • Patel P.N.
      Caring for patients with celiac disease: The role of the pharmacist.
      The small intestine is the main site of injury, but celiac disease is a multisystem disorder, and comorbidities or other autoimmune disorders may develop if it is not treated with a strict gluten-free diet. Celiac disease can present with a wide variety of symptoms including diarrhea, weight loss, failure to thrive, migraines, iron deficiency anemia, osteoporosis, and infertility.
      • Rubio-Tapia A.
      • Rahim M.W.
      • See J.A.
      • Lahr B.D.
      • Wu T.T.
      • Murray J.A.
      Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet.
      Long-term consequences of untreated celiac disease include an increased risk for cancers of the mouth, pharynx, or esophagus and non-Hodgkin’s lymphoma.
      • Mangione R.A.
      • Patel P.N.
      Caring for patients with celiac disease: The role of the pharmacist.
      • Holmes G.K.
      • Prior P.
      • Lane M.R.
      • Pope D.
      • Allan R.N.
      Malignancy in coeliac disease—Effect of a gluten free diet.
      • Rodrigo L.
      Celiac disease.
      It is estimated that celiac disease affects approximately 1% of the population; however, with increased screening and awareness, the incidence in the United States is increasing.
      • Ludvigsson J.F.
      • Rubio-Tapia A.
      • Van Dyke C.T.
      • et al.
      Increasing incidence of celiac Disease in a north American population.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Academy of Nutrition and Dietetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mangione R.A.
        • Patel P.N.
        Caring for patients with celiac disease: The role of the pharmacist.
        J Am Pharm Assoc. 2008; 48: e125-e139
        • Rubio-Tapia A.
        • Rahim M.W.
        • See J.A.
        • Lahr B.D.
        • Wu T.T.
        • Murray J.A.
        Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet.
        Am J Gastroenterol. 2010; 105: 1412-1420
        • Holmes G.K.
        • Prior P.
        • Lane M.R.
        • Pope D.
        • Allan R.N.
        Malignancy in coeliac disease—Effect of a gluten free diet.
        Gut. 1989; 30: 333-338
        • Rodrigo L.
        Celiac disease.
        World J Gastroenterol. 2006; 12: 6585-6593
        • Ludvigsson J.F.
        • Rubio-Tapia A.
        • Van Dyke C.T.
        • et al.
        Increasing incidence of celiac Disease in a north American population.
        Am J Gastroenterol. 2013; 108: 818-824
        • Losowsky M.S.
        A history of coeliac disease.
        Dig Dis. 2008; 26: 112-120
        • Rubio-Tapia A.
        • Hill I.D.
        • Kelly C.P.
        • et al.
        ACG clinical guidelines: Diagnosis and management of celiac disease.
        Am J Gastroenterol. 2013; 108: 656-676
        • Bruins M.J.
        The clinical response to gluten challenge: A review of the literature.
        Nutrients. 2013; 5: 4614-4641
        • Ontiveros N.
        • Tye-Din J.A.
        • Hardy M.Y.
        • Anderson R.P.
        Ex vivo whole blood secretion of interferon (IFN)-γ and IFN-γ-inducible protein-10 measured by enzyme-linked immunosorbent assay are as sensitive as IFN-γ enzyme-linked immunospot for the detection of gluten-reactive T cells in human leucocyte antigen (HLA)-DQ2·5+-associated coeliac disease.
        Clin Exp Immunol. 2014; 175: 305-315
        • Almazan M.V.
        • Ortega E.
        • Tores R.M.
        • et al.
        Diagnostic screening for subclinical celiac disease using a rapid test in children aged 2-4.
        Pediatr Res. 2015; 78: 280-285
        • Haas S.V.
        The value of the banana in the treatment of coeliac disease.
        Am J Dis Child. 1924; 24: 421-437
        • Gottlieb K.
        • Dawson J.
        • Hussain F.
        • Murray J.
        Development of drugs for celiac disease: Review of endpoints for Phase 2 and 3 trials.
        Gastroenterol Rep. 2015; : 1-12
        • Patel D.G.
        • Krogh C.M.
        • Thompson W.G.
        Gluten in pills: A hazard for patients with celiac disease.
        Can Med Assoc J. 1985; 133: 114-115
      1. Food and Drug Administration. Questions and answers: Gluten-free food labeling final rule. www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/Allergens/ucm362880.htm. Accessed January 23, 2018.

        • Collin P.
        • Thorell L.
        • Kaukinen K.
        • Maki M.
        The safe threshold for gluten contamination in gluten-free products. Can trace amounts be accepted in the treatment of coeliac disease?.
        Aliment Pharmacol Ther. 2004; 19: 1277-1283
        • Catassi C.
        • Fabiani E.
        • Iacono G.
        • et al.
        A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease.
        Am J Clin Nutr. 2007; 85: 160-166
        • Catassi C.
        • Fasano A.
        Celiac disease.
        Curr Opin Gastroenterol. 2009; 24: 687-691
        • Mulder C.J.
        • Wierdsma N.F.
        • Berkenpas M.
        • Jacobs M.A.
        • Bouma G.
        Preventing complications in celiac disease: Our experience with managing adult celiac disease.
        Best Pract Res Clin Gastroenterol. 2015; 29: 459-468
        • Kalkat P.K.
        • Baisch D.W.
        • Zipser R.D.
        Hazards of gluten-containing foods and pharmaceuticals for persons with celiac disease.
        Drug Benefit Trends. 2003; 15: 47-48
        • Esteban S.
        • Podder N.
        • Cruciani R.
        Celiac disease: Not all medications are contaminated with gliadin.
        J Pain Symptom Manage. 2006; 31: 195-196
        • Crowe J.P.
        • Falini N.P.
        Gluten in pharmaceutical products.
        Am J Heath Syst Pharm. 2001; 58: 396-401
        • Plogstead S.
        Medications and celiac disease-Tips from a pharmacist.
        Pract Gastroenterol. 2007; 31: 58-64
      2. Pillbox.
        ([database online]) National Institutes of Health, Bethesda, MD2016 (Accessed January 23, 2018)
      3. Jay L, Mangione RA, Pal S, et al. National Foundation for Celiac Awareness. (2014). Gluten in medication: Qualifying the extent of exposure to people with celiac disease and identifying a hidden and preventable cause of an adverse drug event. https://www.beyondceliac.org/SiteData/docs/PublicRepo/74eee1968327b603/Public%20Report%20Final.pdf. Accessed January 23, 2018.

        • Cruz J.E.
        • Cocchio C.
        • Lai P.T.
        • Hermes-DeSantis E.
        Gluten content of medications.
        Am J Health Syst Pharm. 2015; 72: 54-60
        • Maltin V.
        • Charabaty A.
        • Mangione R.
        Medications: A hidden source of gluten.
        Pract Gastroenterol. 2009; 33: 32-38
        • Mangione R.A.
        • Patel P.N.
        • Shin E.
        • Fiebert J.
        Determining the gluten content of nonprescription drugs: Information for patients with celiac disease.
        J Am Pharm Assoc. 2011; 51: 734-737
      4. Gluten in Medicine Disclosure Act of 2013. https://www.govtrack.us/congress/bills/113/hr2003. Accessed January 23, 2018.

        • Claycomb J.
        Pharmacists must guard vulnerable patients against inactive ingredients in medications.
        Drug Topics. 2015;June:21; (http://www.drugtopics.com/drug-topics/news/pharmacists-must-guard-vulnerable-patients-against-inactive-ingredients-medications?page=full. Accessed January 23, 2018.)
      5. Gluten in Medicine Disclosure Act of 2015. https://www.congress.gov/bill/114th-congress/house-bill/3648. Accessed January 23, 2018.

      6. Medications and gluten. https://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/ensuringsafeuseofmedicine/ucm410373.htm. Accessed January 23, 2018.

      Biography

      G. Rubal-Peace is the pharmacy program coordinator, Banner University Medical Center South, Tucson, AZ, and a clinical assistant professor, Department of Pharmacy Practice and Science, University of Arizona, Tucson.

      Biography

      C. Sepp is the Banner Family Pharmacy senior manager, Banner University Medical Center South, Tucson, AZ.

      Linked Article

      • Erratum
        Journal of the Academy of Nutrition and DieteticsVol. 118Issue 12
        • Preview
          There is an error in Figure 1 (p 1366) of the article “Addressing Barriers for Patients with Celiac Disease When Assessing for Gluten in Medications” in the August 2018 issue of the Journal of the Academy of Nutrition and Dietetics. Instead of “dextran or dextrin” the text should read “dextrate or dextrin.” The authors regret this error.
        • Full-Text
        • PDF